Naoko Ohtani

Title: Naoko Ohtani: Innovator in Cancer Treatment

Introduction

Naoko Ohtani is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of cancer treatment, particularly in the area of nonalcoholic steatohepatitis (NASH)-associated liver cancer. With a total of 5 patents to her name, Ohtani's work is paving the way for new therapeutic approaches.

Latest Patents

One of her latest patents focuses on the use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer. This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists that are useful in treating NASH-associated liver cancer in humans or animals. The method involves administering one or more of Compound A, Compound B, or Compound C, or their pharmaceutically acceptable salts, as the EP4 antagonist(s). Additionally, the method may include a pharmaceutical composition comprising the EP4 antagonist, along with one or more other active agents and/or therapies.

Career Highlights

Throughout her career, Naoko Ohtani has worked with notable organizations such as Askat Inc. and the Japanese Foundation for Cancer Research. Her innovative research and dedication to improving cancer treatment have established her as a key figure in the scientific community.

Collaborations

Naoko has collaborated with esteemed colleagues, including Tze Mun Loo and Fumitaka Kamachi. These partnerships have further enhanced her research and contributed to the advancement of cancer therapies.

Conclusion

Naoko Ohtani's contributions to cancer treatment through her innovative patents and collaborations highlight her importance in the field. Her work continues to inspire advancements in medical research and therapy development.